expressTEC
expressTEC is a biotech startup company and a spin-off from the University of Algarve, focusing on transforming cancer care through RNA and AI-based technology. Their primary product, expressPIK, is the first RNA-based test for targeted treatment eligibility, specifically identifying mutations in breast tumors. This platform aims to accurately select patients for targeted therapies, leading to better clinical management, higher survival rates, and improved quality of life, while also reducing healthcare costs and increasing return on drug development investment. The company has received recognition, including the Altice International Innovation Award 2023, and is developing the expressPlatform for broader applications across cancer types. expressTEC is led by experienced researchers and aims to empower healthcare professionals with fast, reliable tools for personalized treatment decisions.
expressTEC
expressTEC is a biotech startup company and a spin-off from the University of Algarve, focusing on transforming cancer care through RNA and AI-based technology. Their primary product, expressPIK, is the first RNA-based test for targeted treatment eligibility, specifically identifying mutations in breast tumors. This platform aims to accurately select patients for targeted therapies, leading to better clinical management, higher survival rates, and improved quality of life, while also reducing healthcare costs and increasing return on drug development investment. The company has received recognition, including the Altice International Innovation Award 2023, and is developing the expressPlatform for broader applications across cancer types. expressTEC is led by experienced researchers and aims to empower healthcare professionals with fast, reliable tools for personalized treatment decisions.